A novel fluorescent imaging agent for diffuse optical tomography of the breast: first clinical experience in patients.
OBJECTIVE
This is the first clinical evaluation of a novel fluorescent imaging agent (Omocianine) for breast cancer detection with diffuse optical tomography (DOT).


METHODS
Eleven women suspected of breast cancer were imaged with DOT at multiple time points (up to 24 h) after receiving an intravenous injection of Omocianine (doses 0.01 to 0.1 mg/kg bodyweight). Breast MRI was obtained for comparison.


RESULTS
Histopathology showed invasive cancer in ten patients and fibroadenoma in one patient. With the lowest dose of Omocianine, two of three lesions were detected; with the second dose, three of three lesions were detected; with the two highest doses, none of five lesions were detected. Lesion location on DOT showed excellent agreement with MRI. Optimal lesion-to-background signals were obtained after 8 h. No adverse events occurred.


CONCLUSIONS
Lowest doses of Omocianine performed best in lesion detection; DOT using a low-dose fluorescent agent is feasible and safe for breast cancer visualization in patients.
Department of Radiology, University Medical Center Utrecht, Utrecht, The Netherlands. s.m.w.y.vandeven-2@umcutrecht.nl
Stephanie
S
van de Ven
Andrea
A
Wiethoff
Tim
T
Nielsen
Bernhard
B
Brendel
Marjolein
M
van der Voort
Rami
R
Nachabe
Martin
M
Van der Mark
Michiel
M
Van Beek
Leon
L
Bakker
Lueder
L
Fels
Sjoerd
S
Elias
Peter
P
Luijten
Willem
W
Mali
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001940:Breast / Q000473:pathology*; D001943:Breast Neoplasms / Q000175:diagnosis / Q000473:pathology; D004058:Diffusion; D005260:Female; D005456:Fluorescent Dyes / Q000009:adverse effects; D006801:Humans; D008875:Middle Aged; D041622:Tomography, Optical / Q000379:methods*; D055815:Young Adult
D005456:Fluorescent Dyes